{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:23:21Z","timestamp":1775478201165,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,12,21]],"date-time":"2003-12-21T00:00:00Z","timestamp":1071964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,12,21]],"date-time":"2003-12-21T00:00:00Z","timestamp":1071964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2004,1,1]]},"DOI":"10.1038\/nm976","type":"journal-article","created":{"date-parts":[[2003,12,31]],"date-time":"2003-12-31T17:59:01Z","timestamp":1072893541000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":939,"title":["Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Tianhong","family":"Wang","sequence":"first","affiliation":[]},{"given":"Guilian","family":"Niu","sequence":"additional","affiliation":[]},{"given":"Marcin","family":"Kortylewski","sequence":"additional","affiliation":[]},{"given":"Lyudmila","family":"Burdelya","sequence":"additional","affiliation":[]},{"given":"Kenneth","family":"Shain","sequence":"additional","affiliation":[]},{"given":"Shumin","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Raka","family":"Bhattacharya","sequence":"additional","affiliation":[]},{"given":"Dmitry","family":"Gabrilovich","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Heller","sequence":"additional","affiliation":[]},{"given":"Domenico","family":"Coppola","sequence":"additional","affiliation":[]},{"given":"William","family":"Dalton","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Jove","sequence":"additional","affiliation":[]},{"given":"Drew","family":"Pardoll","sequence":"additional","affiliation":[]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2003,12,21]]},"reference":[{"key":"BFnm976_CR1","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","volume":"95","author":"DH Kaplan","year":"1998","unstructured":"Kaplan, D.H. et al. Demonstration of an interferon \u03b3-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556\u20137561 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm976_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107\u20131111 (2001).","journal-title":"Nature"},{"key":"BFnm976_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1006\/smim.1996.0035","volume":"8","author":"EJ Fuchs","year":"1996","unstructured":"Fuchs, E.J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271\u2013280 (1996).","journal-title":"Semin. Immunol."},{"key":"BFnm976_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nm0598supp-525","volume":"4","author":"DM Pardoll","year":"1998","unstructured":"Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525\u2013531 (1998).","journal-title":"Nat. Med."},{"key":"BFnm976_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1073\/pnas.231606698","volume":"99","author":"RM Steinman","year":"2002","unstructured":"Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351\u2013358 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm976_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252 (1998).","journal-title":"Nature"},{"key":"BFnm976_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D.I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"BFnm976_CR8","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.4049\/jimmunol.168.9.4333","volume":"168","author":"CC Sombroek","year":"2002","unstructured":"Sombroek, C.C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168, 4333\u20134343 (2002).","journal-title":"J. Immunol."},{"key":"BFnm976_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1074-7613(00)80005-9","volume":"10","author":"K Takeda","year":"1999","unstructured":"Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39\u201349 (1999).","journal-title":"Immunity"},{"key":"BFnm976_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1074-7613(03)00232-2","volume":"19","author":"F Cheng","year":"2003","unstructured":"Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425\u2013436 (2003).","journal-title":"Immunity"},{"key":"BFnm976_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295\u2013303 (1999).","journal-title":"Cell"},{"key":"BFnm976_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","volume":"10","author":"R Catlett-Falcone","year":"1999","unstructured":"Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105\u2013115 (1999).","journal-title":"Immunity"},{"key":"BFnm976_CR13","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1073\/pnas.131568898","volume":"98","author":"T Bowman","year":"2001","unstructured":"Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98, 7319\u20137324 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm976_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","volume":"21","author":"G Niu","year":"2002","unstructured":"Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000\u20132008 (2002).","journal-title":"Oncogene"},{"key":"BFnm976_CR15","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman, T., Garcia, R., Turkson, J. & Jove, R. STATs in oncogenesis. Oncogene 19, 2474\u20132488 (2000).","journal-title":"Oncogene"},{"key":"BFnm976_CR16","first-page":"5059","volume":"59","author":"G Niu","year":"1999","unstructured":"Niu, G. et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59, 5059\u20135063 (1999).","journal-title":"Cancer Res."},{"key":"BFnm976_CR17","first-page":"3276","volume":"61","author":"G Niu","year":"2001","unstructured":"Niu, G. et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 61, 3276\u20133280 (2001).","journal-title":"Cancer Res."},{"key":"BFnm976_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","volume":"54","author":"CA Janeway Jr.","year":"1989","unstructured":"Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1\u201313 (1989).","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"BFnm976_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.272.5258.50","volume":"272","author":"DT Fearon","year":"1996","unstructured":"Fearon, D.T. & Locksley, R.M. The instructive role of innate immunity in the acquired immune response. Science 272, 50\u201354 (1996).","journal-title":"Science"},{"key":"BFnm976_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0952-7915(97)80152-5","volume":"9","author":"R Medzhitov","year":"1997","unstructured":"Medzhitov, R. & Janeway, J.C.A. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4\u20139 (1997).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnm976_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/15200","volume":"5","author":"S Gallucci","year":"1999","unstructured":"Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249\u20131255 (1999).","journal-title":"Nat. Med."},{"key":"BFnm976_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","volume":"106","author":"I Mellman","year":"2001","unstructured":"Mellman, I. & Steinman, R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255\u2013258 (2001).","journal-title":"Cell"},{"key":"BFnm976_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1084\/jem.185.3.453","volume":"185","author":"MB Bloom","year":"1997","unstructured":"Bloom, M.B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453\u2013459 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnm976_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1074-7613(00)00052-2","volume":"13","author":"JE Slansky","year":"2000","unstructured":"Slansky, J.E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13, 529\u2013538 (2000).","journal-title":"Immunity"},{"key":"BFnm976_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1074-7613(01)00101-7","volume":"14","author":"ML McLemore","year":"2001","unstructured":"McLemore, M.L. et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14, 193\u2013204 (2001).","journal-title":"Immunity"},{"key":"BFnm976_CR26","first-page":"4485","volume":"60","author":"P Brossart","year":"2000","unstructured":"Brossart, P. et al. Tumor necrosis factor \u03b1 and CD40 ligand antagonize the inhibitory effect of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60, 4485\u20134492 (2000).","journal-title":"Cancer Res."},{"key":"BFnm976_CR27","doi-asserted-by":"publisher","first-page":"27954","DOI":"10.1074\/jbc.271.44.27954","volume":"271","author":"RM Weber-Nordt","year":"1996","unstructured":"Weber-Nordt, R.M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine- phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954\u201327961 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnm976_CR28","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1096\/fj.02-1084fje","volume":"17","author":"M Bartoli","year":"2003","unstructured":"Bartoli, M. et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 17, 1562\u20131564 (2003).","journal-title":"FASEB J."},{"key":"BFnm976_CR29","doi-asserted-by":"publisher","first-page":"45443","DOI":"10.1074\/jbc.M107527200","volume":"276","author":"J Turkson","year":"2001","unstructured":"Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 276, 45443\u201345455 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnm976_CR30","first-page":"809","volume-title":"Inflammation","author":"JM Davidson","year":"1992","unstructured":"Davidson, J.M. Wound repair. in Inflammation (ed. J.L. Gallin) 809\u2013819 (Garland Press, New York, 1992)."},{"key":"BFnm976_CR31","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1093\/emboj\/18.17.4657","volume":"18","author":"S Sano","year":"1999","unstructured":"Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18, 4657\u20134668 (1999).","journal-title":"EMBO J."},{"key":"BFnm976_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.155.2.557","volume":"155","author":"JL Urban","year":"1982","unstructured":"Urban, J.L., Burton, R.C., Holand, J.M., Kripke, M.L. & Schreiber, H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155, 557\u2013573 (1982).","journal-title":"J. Exp. Med."},{"key":"BFnm976_CR33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1084\/jem.157.3.1040","volume":"157","author":"C Uyttenhove","year":"1983","unstructured":"Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040\u20131052 (1983).","journal-title":"J. Exp. Med."},{"key":"BFnm976_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/304165a0","volume":"304","author":"RD Wortzel","year":"1983","unstructured":"Wortzel, R.D., Philipps, C. & Schreiber, H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304, 165\u2013167 (1983).","journal-title":"Nature"},{"key":"BFnm976_CR35","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/35082583","volume":"411","author":"AF Ochsenbein","year":"2001","unstructured":"Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058\u20131064 (2001).","journal-title":"Nature"},{"key":"BFnm976_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1074-7613(02)00336-9","volume":"17","author":"CK Lee","year":"2002","unstructured":"Lee, C.K. et al. Stat3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17, 63\u201372 (2002).","journal-title":"Immunity"},{"key":"BFnm976_CR37","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1128\/MCB.18.5.2545","volume":"18","author":"J Turkson","year":"1998","unstructured":"Turkson, J. et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 18, 2545\u20132552 (1998).","journal-title":"Mol. Cell Biol."},{"key":"BFnm976_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.191.3.541","volume":"191","author":"Z Lu","year":"2000","unstructured":"Lu, Z. et al. CD-40-independent pathways of T cell help for priming of CD8+ cytotoxic T lymphocytes. J. Exp. Med. 191, 541\u2013550 (2000).","journal-title":"J. Exp. Med."}],"updated-by":[{"DOI":"10.1038\/nm0204-209b","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm976.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm976","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm976.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:36:06Z","timestamp":1684449366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,21]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"alternative-id":["BFnm976"],"URL":"https:\/\/doi.org\/10.1038\/nm976","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,21]]},"assertion":[{"value":"10 October 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}